Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by chipmuki1234567on Dec 20, 2016 4:48pm
146 Views
Post# 25626891

Why did we sell shares @ 0.15?

Why did we sell shares @ 0.15?So this company is going down the dilution path.... I see a reverse split of 10 to 1 pretty soon as the management of this company is pure suspect in terms of how they are running this company. What was the Citagenix purchase all about huh? Its a loss making business that the previous owners were milking. Cut the work force, your revenue does not support such a big workforce. Also, lets review the management layer... this stinks of mismanagement. Everyone is excited about ATB-346, and rightfully so, but come on ATB-346 is the future. Get citagenix in line so you can have the $2-4M you need annually to keep ATB-346 float. Is that not why you bought Citagenix? They lack a strong CFO. This is turning out to be a joke. I am not buying anymore shares and writing off w.e. I got so far. While I love skin in the game, this is the issue with skin in the game. If the management is bad, skin in the game allows them to hold onto their jobs. I think there is some house cleaning that needs to be done here or this Co is no going to create any shareholder value. NicoOx was the last company John Wallace was involved in, and that crapped out. Look at the guys twitter, makes you wonder if he should have controlling shares. Fix CITAGENIX ASAP. Make it profitable within 2017.
Bullboard Posts